BEF, Author at The Boomer Esiason Foundation

March 19, 2019

Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with Aeroquin™ (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans. Trial results demonstrated statistically significant improvements...

Azithromycin Doesn’t Always Help Lungs in CF Patients Without P. Aeruginosa, Study Finds

by BEF

CF News, Therapies

March 19, 2019

Children and adolescents with cystic fibrosis who received the antibiotic azithromycin did not experience improved lung function, compared with patients who received placebo, according to a study published in the May 5 issue of the Journal of the American Medical Association. "A vicious cycle of infection...

Raptor Announces Qualified Infectious Disease Product

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE: Original Press Release Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled LevofloxacinGranted for Three Distinct Indications: Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis and in Patients with Non-Cystic Fibrosis Bronchiectasis as well as in Patients with Nontuberculous MycobacteriaPre-NDA Discussion...

Kalydeco Wins First Annual Forbes Breakthrough Drug Award via Forbes.com

by BEF

Boomer Esiason Foundation, CF Community, CF News, Research, Therapies

March 19, 2019

SOURCEKalydeco, a treatment for cystic fibrosis developed by Vertex Pharmaceuticals VRTX +2.40% with support from the Cystic Fibrosis Foundation , was awarded the first Forbes Breakthrough Drug Award today for dramatically improving the lives of patients and conquering a scientific challenge that had vexed researchers...

CF Mutation May Change How Proteins Communicate via CF News Today

by BEF

CF Community, CF News, Research

March 19, 2019

Original Post Protein interactions could be misdirected in people with cystic fibrosis (CF), causing a loss of normal protein function, according to researchers from the Scripps Research Institute (TSRI) in San Diego, California. The new study, titled “∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis“...

Vertex Announces Significant Progress in Development via Vertex

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE - OFFICIAL PRESS RELEASE Vertex Announces Significant Progress in Its Development Efforts to Treat the Cause of Cystic Fibrosis in the Vast Majority of People with the Disease-Two next-generation correctors to enter clinical development in November; studies of a triple combination of a next-generation corrector...

ORKAMBI™ Is Now FDA Approved!

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

ORKAMBI is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 12 years and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene. ORKAMBI should not be used in patients other than those who have two...

CFFT Grants $5 Million to Celtaxsys’ Phase 2 Cystic Fibrosis Study via CF News Today

by BEF

CF News, Research, Therapies

March 19, 2019

ORIGINAL PRESS RELEASE Celtaxsys has announced that the company’s phase 2 clinical trial to evaluate CTX-4430, its investigational treatment forcystic fibrosis (CF), will be supported by a $5 million grant from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The CFFT is the non-profit drug discovery and development affiliate...

FDA Panel Recommends Approval of ORKAMBI™ via Vertex

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE --- Please read the original press release here --- SOURCE FDA decision expected by July 5, 2015 PDUFA date Approximately 8,500 people with cystic fibrosis in the U.S. have two copies of the F508del mutation and are ages 12 and older BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)...

Yale scientists use gene editing to correct mutation in cystic fibrosis via Yale News

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE Yale researchers successfully corrected the most common mutation in the gene that causes cystic fibrosis, a lethal genetic disorder. The study was published April 27 in Nature Communications. Cystic fibrosis is an inherited, life-threatening disorder that damages the lungs and digestive system. It is most commonly caused...

Author: BEF

Mpex Presents Positive Phase 2 Clinical Trial Results of Aeroquin Treatment in CF

Azithromycin Doesn’t Always Help Lungs in CF Patients Without P. Aeruginosa, Study Finds

Raptor Announces Qualified Infectious Disease Product

Kalydeco Wins First Annual Forbes Breakthrough Drug Award via Forbes.com

CF Mutation May Change How Proteins Communicate via CF News Today

Vertex Announces Significant Progress in Development via Vertex

ORKAMBI™ Is Now FDA Approved!

CFFT Grants $5 Million to Celtaxsys’ Phase 2 Cystic Fibrosis Study via CF News Today

FDA Panel Recommends Approval of ORKAMBI™ via Vertex

Yale scientists use gene editing to correct mutation in cystic fibrosis via Yale News

Never miss an update. Subscribe to our emails!